109 related articles for article (PubMed ID: 33399707)
1. [Pharmacogenomics of vitamin K antagonists].
Guzmán N; Vega M; Reyes F; Guzmán-Oyarzo D; Andaur M; Boguen R; Letelier P
Rev Med Chil; 2020 Sep; 148(9):1307-1314. PubMed ID: 33399707
[TBL] [Abstract][Full Text] [Related]
2. Warfarin pharmacogenomics: recommendations with available patented clinical technologies.
Borkowski AA; Kardani A; Mastorides SM; Thomas LB
Recent Pat Biotechnol; 2014; 8(2):110-5. PubMed ID: 25185986
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics aspects of oral anticoagulants therapy.
Militaru FC; Vesa SC; Pop TR; Buzoianu AD
J Med Life; 2015; 8(2):171-5. PubMed ID: 25866574
[TBL] [Abstract][Full Text] [Related]
4. Extremely low therapeutic doses of acenocoumarol in a patient with
Chaidaroglou A; Kanellopoulou T; Panopoulos G; Stavridis G; Degiannis D
Pharmacogenomics; 2019 Apr; 20(5):311-317. PubMed ID: 30983536
[TBL] [Abstract][Full Text] [Related]
5. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes: comment.
Gaikwad T; Ghosh K; Shetty S
J Thromb Haemost; 2017 Aug; 15(8):1708. PubMed ID: 28608988
[No Abstract] [Full Text] [Related]
6. [Oral anticoagulation and pharmacogenetics: importance in the clinical setting].
Benusiglio PR; Desmeules J; de Moerloose P; Dayer P
Rev Med Suisse; 2007 Sep; 3(124):2030, 2033-4, 2036. PubMed ID: 17955831
[TBL] [Abstract][Full Text] [Related]
7. [Genetic determinants of response to vitamin K antagonists].
Mundi S; Distante A; De Caterina R
G Ital Cardiol (Rome); 2014 Sep; 15(9):482-93. PubMed ID: 25298357
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacogenetic algorithms for predicting the appropriate dose of vitamin K antagonists: are they still useful?].
Mundi S; Distante A; De Caterina R
G Ital Cardiol (Rome); 2014 Oct; 15(10):546-60. PubMed ID: 25424019
[TBL] [Abstract][Full Text] [Related]
9. Influence of proton pump inhibitors and VKORC1 mutations on CYP2C9-mediated dose requirements of vitamin K antagonist therapy: a pilot study.
Brunner-Ziegler S; Jilma B; Magirr D; Sunder-Plassmann R; Giurgea GA; Hammer A; Margeta C; Brunner M; Koppensteiner R; Mannhalter C
Br J Haematol; 2014 Nov; 167(4):547-53. PubMed ID: 25142093
[TBL] [Abstract][Full Text] [Related]
10. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
[TBL] [Abstract][Full Text] [Related]
11. Genetic, clinical and behavioural determinants of vitamin K-antagonist dose--explored through multivariable modelling and visualization.
Skov J; Bladbjerg EM; Rasmussen MA; Sidelmann JJ; Leppin A; Jespersen J
Basic Clin Pharmacol Toxicol; 2012 Feb; 110(2):193-8. PubMed ID: 21895980
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of vitamin K antagonists: useful or hype?
Lippi G; Franchini M; Favaloro EJ
Clin Chem Lab Med; 2009; 47(5):503-15. PubMed ID: 19397481
[TBL] [Abstract][Full Text] [Related]
13. Development and Comparison of Warfarin Dosing Algorithms in Stroke Patients.
Cho SM; Lee KY; Choi JR; Lee KA
Yonsei Med J; 2016 May; 57(3):635-40. PubMed ID: 26996562
[TBL] [Abstract][Full Text] [Related]
14. Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome.
Ghozlan MF; Foad DA; Darwish YW; Saad AA
Blood Coagul Fibrinolysis; 2015 Jul; 26(5):499-504. PubMed ID: 25699611
[TBL] [Abstract][Full Text] [Related]
15. What is the role of pharmacogenetics in optimization of warfarin dosing?
Carnes CA
Trends Cardiovasc Med; 2015 Jan; 25(1):42-3. PubMed ID: 25476743
[No Abstract] [Full Text] [Related]
16. Pharmacogenetics of Warfarin Therapy.
Ruff CT
Clin Chem; 2018 Nov; 64(11):1558-1559. PubMed ID: 29941467
[No Abstract] [Full Text] [Related]
17. Pharmacogenetics-Based Warfarin Dosing in Patients With Cardiac Valve Replacement: The Effects of CYP2C9 and VKORC1 Gene Polymorphisms.
Farzamikia N; Sakhinia E; Afrasiabirad A
Lab Med; 2017 Dec; 49(1):25-34. PubMed ID: 29182754
[TBL] [Abstract][Full Text] [Related]
18. Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves.
An SH; Chang BC; Lee KE; Gwak HS
Cardiovasc Ther; 2015 Dec; 33(6):324-8. PubMed ID: 26223945
[TBL] [Abstract][Full Text] [Related]
19. Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans.
Hernandez W; Gamazon ER; Aquino-Michaels K; Patel S; O'Brien TJ; Harralson AF; Kittles RA; Barbour A; Tuck M; McIntosh SD; Douglas JN; Nicolae D; Cavallari LH; Perera MA
Pharmacogenomics J; 2014 Jun; 14(3):223-8. PubMed ID: 24018621
[TBL] [Abstract][Full Text] [Related]
20. Warfarin dosing and the promise of pharmacogenomics.
Dumas TE; Hawke RL; Lee CR
Curr Clin Pharmacol; 2007 Jan; 2(1):11-21. PubMed ID: 18690851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
